Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to first year apprentice Katie Chegwin on completing her Level 3 Apprenticeship in Business and Administration.

Katie is the first apprentice to go on to do a Level 4 Business and Administration apprenticeship, under the scheme at the University of Oxford.

Working as a Clinical Trials Support Officer for the Oxford Clinical Trials Research Unit (OCTRU), Katie's main role is administration support for the Hub Team, this includes taking bookings for training, taking meeting minutes and keeping the OCTRU website up to date. Her role is varied and also includes assisting on some of the OCTRU trials with tasks such as entering patient data, checking incoming trial data for completeness and validity or support in event management.

I believe developing and applying your knowledge and skills on real projects in a workplace environment, whilst being paid, is a fantastic way to start a career.
- Katie Chegwin

Katie works regularly with the different groups that make up OCTRU, such as Oxford Trauma, RRIO and OCTO, and is right on track to achieving her Business and Administration qualifications whilst training and working on the job.

"This first year as an apprentice at OCTRU has given me problem-solving and time management skills, as well as a boost in my confidence and attitude to new projects. I'm very thankful to both my line manager, Emma Haines, and college tutor, Sonja, for the mentoring and supporting", says Katie.

She adds: "I believe developing and applying your knowledge and skills on real projects in a workplace environment, whilst being paid, is a fantastic way to start a career."

Having an apprentice in the team is a valuable experience for both the apprentice and the employer, as Katie's line manager, Emma Haines explains: "Katie has had an excellent first year with OCTRU and has become a very valued member of our team. Since joining OCTRU Katie's self-confidence has increased and she will happily take on any task she is asked to do and frequently uses her own initiative. Her friendly and helpful personality has made it a pleasure to support her in her Apprenticeship. Katie is a great example of how effective apprenticeships can be for both employer and learner and I am sure she will continue to grow and develop in her role and achieve her Level 4 diploma."

Level 3 of the Apprenticeship Scheme included four mandatory units plus a few optional ones, chosen by the apprentice with the line manager and the college assessor to ensure you can target both your employer's and your interests. Katie did her Level 3 at Abingdon and Witney College (going to college on day-release for a 10 week period) and will now do her Level 4 at Henley College (going to college once a month).

Find out more about apprenticeships with the University of Oxford here and in Oxfordshire here.

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.